According to Zhitong Finance App News, Xinhua Healthcare (600587.SH) released its 2023 annual report. During the reporting period, the company achieved operating income of 10.012 billion yuan, up 7.87% year on year; net profit attributable to shareholders of listed companies was 654 million yuan, up 30.78% year on year; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 619 million yuan, up 23.20% year on year; basic earnings per share were 1.43 yuan/share.

Based on the total share capital, the company plans to distribute 5 yuan in cash (tax included) to all shareholders for every 10 shares, with a total cash dividend of RMB 233,340,994.50. At the same time, the company plans to transfer 3 shares for every 10 shares by transferring capital stock to all shareholders.

The company follows the management policy of “restructuring and strengthening the main business to improve efficiency and prevent risks”. The company focuses on the main business, concentrating its advantages on developing manufactured products in the medical equipment, pharmaceutical equipment and other sectors. The company's revenue structure has been significantly optimized, and the proportion of revenue achieved by the company's manufactured products in the operating income continues to increase. During the reporting period, the revenue achieved by the company's medical device manufacturing products and pharmaceutical equipment products increased to 61.49% of the main business revenue, an increase of 16.84 percentage points compared with 44.65% in 2020.